US Market Report for Nuclear Medicine Imaging 2016 - MedCore

Publisher Name :
Date: 01-Sep-2016
No. of pages: 96
Inquire Before Buying

Description

PET/CT systems will continue to represent the largest segment in the nuclear medicine system market throughout the forecast, primarily due to its significantly higher ASP. In contrast, SPECT scanners represented the smallest segment. SPECT/CT scanners are cannibalizing the SPECT market as they offer increase patient benefits, namely the ability to superimpose a SPECT scan over a CT scan, which allows the physician to obtain more information. Despite the higher rate of growth and larger sales volume, the SPECT/CT segment will not overtake the PET/CT segment in terms of market share throughout the forecast as a result of the high ASP commanded by PET/CT devices.

Abstract

The U.S. market for nuclear medicine imaging includes positron emission tomography/computed tomography (PET/CT), single photon emission computed tomography (SPECT) and single photon emission computed tomography/computed tomography (SPECT/CT). In 2015, PET/CT systems represented the largest segment of the overall market.

Companies


  • GE Healthcare

  • Siemens Healthcare

  • Philips Healthcare

  • Bayer

  • Hologic

  • Toshiba Medical Systems


Others include: Accutome, Agfa Healthcare, Amrad Medical, Analogic, Arcoma-IMIX, Assured Imaging Mobile Mammography, BK Medical, Bracco, C.R. Bard, Canon, Carestream Health, CMR-Naviscan, Cuattro, Del Medical, Digirad, Dilon Technologies, Ellex/Innovative Imaging, Esaote, eZono, Fischer-Giotto, FONAR, Fujifilm, Gamma Medica Inc., Guerbet, Hitachi Medical Systems, iCRco, Imaging Dynamics Company, IMRIS, Konica Minolta, Lakeshore Technologies Inc., Lantheus Medical Imaging, Machnet B.V., Mallinckrodt, MILabs, Mindray, Neusoft Medical Systems, Paradigm, Planmed OY, Quantel Medical, Rayence, Samsung Medison, Shimadzu, SonoCiné, Sonogage, Sonomed Escalon, SonoSite, Spectrum Dynamics Medical, SuperSonic Imagine, SuperSonic Imagine, Swissray, Teleflex, Terason, Tomey, TXR, ViewRay, Zonare, etc.

US Market Report for Nuclear Medicine Imaging 2016 - MedCore

Table of Contents

Table Of Contents I
List Of Figures Xx
List Of Charts Xxv

Executive Summary 1
U.S. Medical Imaging Device Market Overview 1
Competitive Analysis 3
Market Trends 6
Market Developments 8
Procedure Codes Investigated 9
Procedures Included 12
Markets Included 16
Key Report Updates 19
Version History 19

Research Methodology 20
1.1 Research Scope 20
1.2 Idata's 9-Step Methodology 20
Step 1: Project Initiation & Team Selection 20
Step 2: Prepare Data Systems and Perform Secondary Research 22
Step 3: Preparation for Interviews & Questionnaire Design 23
Step 4: Performing Primary Research 24
Step 5: Research Analysis: Establishing Baseline Estimates 26
Step 6: Market Forecast and Analysis 27
Step 7: Identify Strategic Opportunities 29
Step 8: Final Review and Market Release 30
Step 9: Customer Feedback and Market Monitoring 31

Product Assessment 32
2.1 Product Portfolios 32
2.1.1 Nuclear Medicine Imaging 32
2.1.1.1 PET/CT 33
2.1.1.2 SPECT 34
2.1.1.3 SPECT/CT Devices 35
2.2 Clinical Trials 36
2.2.1 Bayer 37
2.2.2 Bracco 37
2.2.3 Carestream Health 40
2.2.4 Fujifilm 43
2.2.5 GE Healthcare 46
2.2.6 Guerbet 63
2.2.7 Hologic 67
2.2.8 Lantheus Medical Imaging 68
2.2.9 Philips Healthcare 68
2.2.10 Siemens Healthcare 75
2.2.11 Toshiba Medical Systems 77

Nuclear Medicine Imaging Market 79
3.1 Market Overview 79
3.2 Market Analysis And Forecast 83
3.2.1 PET/CT Market 83
3.2.2 SPECT Market 85
3.2.3 SPECT/CT Market 87
3.3 Drivers And Limiters 89
3.3.1 Market Drivers 89
3.3.2 Market Limiters 89
3.4 Competitive Market Share Analysis 91

Abbreviations 94

Appendix: Company Press Releases 96

List of Charts

Chart 1 1: Medical Imaging Device Market by Segment, U.S., 2012 - 2022 2
Chart 1 2: Medical Imaging Device Market Overview, U.S., 2012 & 2022 2
Chart 3 1: Nuclear Medicine Imaging Market by Segment, U.S., 2012 - 2022 81
Chart 3 2: Nuclear Medicine Imaging Market Breakdown, U.S., 2015 82
Chart 3 3: Nuclear Medicine Imaging Market Breakdown, U.S., 2022 82
Chart 3 4: PET/CT Market, U.S., 2012 - 2022 84
Chart 3 5: SPECT Market, U.S., 2012 - 2022 86
Chart 3 6: SPECT/CT Market, U.S., 2012 - 2022 88
Chart 3 7: Leading Competitors, Nuclear Medicine Imaging Market, U.S., 2015 93

List of Figures

Figure 1 1: Medical Imaging Device Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2) 3
Figure 1 2: Medical Imaging Device Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2) 3
Figure 1 3: Companies Researched in this Report, U.S., 2015 (1 of 2) 4
Figure 1 4: Companies Researched in this Report, U.S., 2015 (2 of 2) 5
Figure 1 5: Factors Impacting the Medical Imaging Device Market by Segment, U.S. (1 of 2) 6
Figure 1 6: Factors Impacting the Medical Imaging Device Market by Segment, U.S. (2 of 2) 7
Figure 1 7: Recent Events in the Medical Imaging Device Market, U.S., 2012 - 2015 8
Figure 1 8: Procedure Codes Investigated, U.S., 2015 (1 of 3) 9
Figure 1 9: Procedure Codes Investigated, U.S., 2015 (2 of 3) 10
Figure 1 10: Procedure Codes Investigated, U.S., 2015 (3 of 3) 11
Figure 1 11: Medical Imaging Procedures Covered, U.S., 2015 (1 of 4) 12
Figure 1 12: Medical Imaging Device Markets Covered, U.S., 2015 (1 of 3) 16
Figure 1 13: Medical Imaging Device Markets Covered, U.S., 2015 (2 of 3) 17
Figure 1 14: Medical Imaging Device Markets Covered, U.S., 2015 (3 of 3) 18
Figure 1 15: Key Report Updates 19
Figure 1 16: Version History 19
Figure 2 1: PET/CT Devices by Company 34
Figure 2 2: SPECT Devices by Company 34
Figure 2 3: SPECT/CT Devices by Company 35
Figure 2 4: Perfusion CT as a Predictor for Response to Antiangiogenic Therapy 37
Figure 2 5: A Multicenter Study of Iomeron®-400 37
Figure 2 6: Retrospective Study of MRI in Pediatric Patients 38
Figure 2 7: A Pilot Trial Using BR55 Ultrasound Contrast Agent 38
Figure 2 8: Crossover Comparison of MultiHance and Dotarem (BENEFIT) 38
Figure 2 9: Multidetector Computed Tomography (MDCT) Tailored Protocol 39
Figure 2 10: Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body 39
Figure 2 11: Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body 40
Figure 2 12: CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol (CTP) 40
Figure 2 13: Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis 41
Figure 2 14: Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors 41
Figure 2 15: Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors 42
Figure 2 16: Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol (LLI-MSE) 42
Figure 2 17: A Multi-Reader Multi-Case Pivotal Trial 43
Figure 2 18: Pilot Mammography Reader Study 43
Figure 2 19: Acquisition of Breast Mammography Images 44
Figure 2 20: Study Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI) 44
Figure 2 21: Pilot 3D Mammography Reader Study to Assess Breast Cancer Detection 44
Figure 2 22: Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury (TOMO) 45
Figure 2 23: Collection of FUJIFILM's 3Dimensional Mammograms (3DM) 45
Figure 2 24: International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients 46
Figure 2 25: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase2) 46
Figure 2 26: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis 47
Figure 2 27: Non-invasive Quantification of Liver Iron With MRI 47
Figure 2 28: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis 48
Figure 2 29: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis 48
Figure 2 30: Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit (Firefly) 49
Figure 2 31: Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy 49
Figure 2 32: Clinical Evaluation of an Integrated PET/MRI System (PET/MR_ZURICH) 50
Figure 2 33: Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening 50
Figure 2 34: Development of an Integrated PET/MR System, Accessories and Components 51
Figure 2 35: Comparison of 18F FDG PET/CT TO PET MRI (PET/MR US) 51
Figure 2 36: Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images 52
Figure 2 37: Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView 52
Figure 2 38: Clinical Evaluation for GE CT System 53
Figure 2 39: A Case Collection Study for Digital Breast Tomosynthesis (DBT) 53
Figure 2 40: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection 54
Figure 2 41: Magnetic Resonance Imaging Using Innovative Pulse Sequences 54
Figure 2 42: MRI Scanning of People With MR Safe Orthopedic Implants That Are Made of Metal (MRI) 54
Figure 2 43: Contrast Ultrasound Detection of Sentinel Lymph Nodes 55
Figure 2 44: Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer 55
Figure 2 45: PET/CT for Staging Rectal Cancer Patients With and Without EMVI-MR 56
Figure 2 46: Contrast Enhanced Spectral Mammography (CESM) Study (CONTEND) 56
Figure 2 47: Assessment of Automated Breast Ultrasound 57
Figure 2 48: Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging 57
Figure 2 49: How Beta-amyloid Imagining Influences Clinician Diagnosis and Management 58
Figure 2 50: Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas 58
Figure 2 51: Use of MIBG Scan Images in PVC Ablations (PVC-MIBG) 58
Figure 2 52: Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI 59
Figure 2 53: Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques 59
Figure 2 54: A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide 60
Figure 2 55: 123I-mIBG SPECT Imaging 60
Figure 2 56: Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI (Flucipro) 61
Figure 2 57: FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients 61
Figure 2 58: The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease 62
Figure 2 59: Imaging Biomarkers of Delayed Sequelae in Trauma Brain Injury 62
Figure 2 60: Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization (In-Live) 63
Figure 2 61: P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) 63
Figure 2 62: Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI 64
Figure 2 63: Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI 64
Figure 2 64: Evaluation of Gadoterate in Patients With Decreased Kidney Function 65
Figure 2 65: Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer 65
Figure 2 66: Hepatic Xenetix-CT Perfusion 66
Figure 2 67: Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis 66
Figure 2 68: Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography 67
Figure 2 69: Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis 67
Figure 2 70: Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI 68
Figure 2 71: Virtual Path Planning for Image-guided Needle Interventions 68
Figure 2 72: Applications of Dual-Energy Computed Tomography 69
Figure 2 73: X-ray Dose Reduction Study for Cardiac Angiography and Intervention 69
Figure 2 74: X-ray Dose Reduction Study for Endovascular Interventional Radiology 69
Figure 2 75: X-ray Dose Reduction in Electrophysiology 70
Figure 2 76: Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound 70
Figure 2 77: MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer 70
Figure 2 78: Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids (SOFIA) 71
Figure 2 79: Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter 71
Figure 2 80: Percutaneous Closure of Atrial Septal Defects in Children 72
Figure 2 81: Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy 72
Figure 2 82: Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking 73
Figure 2 83: Chest Ultrasound of ER Patients With Cough or SOB 73
Figure 2 84: The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer 74
Figure 2 85: Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation 74
Figure 2 86: MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases 75
Figure 2 87: Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging 75
Figure 2 88: Evaluation of an Innovative Medical Device Supporting Orthopedic Surgical Interventions (VIPS) 76
Figure 2 89: PET/MRI in Patients With Suspected Prostate Cancer 76
Figure 2 90: Perfusion CT as a Predictor for Response to Antiangiogenic Therapy 77
Figure 2 91: Verification of the Quantitative Accuracy of the PET/CT System Imaging Chain 77
Figure 2 92: General Investigative MRI Protocol 78
Figure 3 1: Nuclear Medicine Imaging Market by Segment, U.S., 2012 - 2022 (US$M) 80
Figure 3 2: PET/CT Market, U.S., 2012 - 2022 83
Figure 3 3: SPECT Market, U.S., 2012 - 2022 85
Figure 3 4: SPECT/CT Market, U.S., 2012 - 2022 87
Figure 3 5: Drivers and Limiters, Nuclear Medicine Imaging Market, U.S., 2015 90
Figure 3 6: Leading Competitors, Nuclear Medicine Imaging Market, U.S., 2015 92
Figure 5 1: Press Release Summary 97

  • Global Nuclear Imaging Equipment Sales Market Report 2017
    Published: 19-Oct-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the global Nuclear Imaging Equipment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (Units), revenue (Million USD), market share and growth rate of Nuclear Imaging Equipment for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe......
  • United States Gamma Camera Market Report 2017
    Published: 09-Oct-2017        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Gamma Camera market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Gam......
  • Global Nuclear Imaging Equipment Market Research Report 2017
    Published: 09-Oct-2017        Price: US 2900 Onwards        Pages: 105
    In this report, the global Nuclear Imaging Equipment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Nuclear Imaging Equipment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe ......
  • Global and Regional Gamma Camera Market Research Report 2017
    Published: 06-Oct-2017        Price: US 3500 Onwards        Pages: 130
    Summary Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Large type - Small type By Application - Thyroid scanning - Molecular breast imaging - Kidney scanning By Company - GE - Philips - Siemens - Digirad - Mediso - MIE - DDD Diagnostic - Dilon Technolo......
  • Global Nuclear Medicine/Radiopharmaceuticals Market Size, Status and Forecast 2022
    Published: 05-Oct-2017        Price: US 3300 Onwards        Pages: 99
    This report studies the global Nuclear Medicine/Radiopharmaceuticals market, analyzes and researches the Nuclear Medicine/Radiopharmaceuticals development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Cardinal Health - Mallinckrodt - GE Healthcare - Lantheus Medical Imaging - Bayer - Bracco Imaging - Eczacibasi-Monrol Nuclear Products - Nordi......
  • Global Gamma Camera Sales Market Report 2017
    Published: 04-Oct-2017        Price: US 4000 Onwards        Pages: 110
    In this report, the global Gamma Camera market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (Units), revenue (Million USD), market share and growth rate of Gamma Camera for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Sou......
  • Global Gamma Camera Market Research Report 2017
    Published: 22-Sep-2017        Price: US 2900 Onwards        Pages: 110
    In this report, the global Gamma Camera market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gamma Camera in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Belgium Nuclear Imaging Equipment Market Outlook to 2022
    Published: 01-Sep-2017        Price: US 4995 Onwards        Pages: 27
    Belgium Nuclear Imaging Equipment Market Outlook to 2022 Summary GlobalData's new report, "Belgium Nuclear Imaging Equipment Market Outlook to 2022", provides key market data on the Belgium Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Single Photon Emission Computed Tomography (SPECT) Systems, Positron Emission Tomography (PET) Systems, Positron Emission Tomogr......
  • Chile Nuclear Imaging Equipment Market Outlook to 2022
    Published: 01-Sep-2017        Price: US 4995 Onwards        Pages: 22
    Chile Nuclear Imaging Equipment Market Outlook to 2022 Summary GlobalData's new report, "Chile Nuclear Imaging Equipment Market Outlook to 2022", provides key market data on the Chile Nuclear Imaging Equipment market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Single Photon Emission Computed Tomography (SPECT) Systems, Positron Emission Tomography (PET) Systems, Positron Emission Tomography/C......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs